Neovascular Glaucoma After a Retinal Vein Occlusion: The 90-Day Warning Window
Neovascular Glaucoma After a Vein Occlusion at a Glance
Call your eye doctor the same day if the eye with the vein occlusion starts to hurt or turn red. A fast rise in eye pressure can cause any of these:
- Deep aching or severe eye pain, or pain in the brow above the eye.
- A red eye that does not settle down.
- New halos around lights, or new blur on top of the vision loss you already had.
- Headache with nausea or vomiting.
- New light sensitivity in that eye.
People with these signs should be checked by an eye doctor as soon as possible1. This is treatable. Care at that visit uses medicine to lower the pressure, plus injections or laser aimed at the blood vessels behind it, and in many cases some sight can be preserved when the problem is found and treated early2. If you cannot reach your eye doctor, go to an emergency room.
Neovascular glaucoma is high pressure inside the eye caused by new, fragile blood vessels growing where they do not belong. Neovascular simply means new vessel. It is a secondary glaucoma, which means another problem that reduced blood flow to the retina set it off2. The retina is the light-sensing film at the back of your eye. The new vessels grow across the iris, the colored ring, and into the drainage angle, the gutter where fluid leaves the eye. When that gutter clogs, pressure climbs. Not every vein blockage does this. An American Academy of Ophthalmology clinical review points to the ischemic type of central retinal vein blockage, where a large area of retina loses its blood supply, as a leading cause of this glaucoma3.
Clinicians sometimes call this 90-day glaucoma because it commonly shows up about three months after the blocking event, and although cases are reported from two weeks to several years afterward, most arrive inside the first six months3. One review reported that more than 80 of every 100 cases develop within six to eight months4. That is why your retina specialist wants frequent looks during months when your vision feels unchanged.
Most people who have a vein occlusion never develop neovascular glaucoma, and the risk is not spread evenly. In the Central Vein Occlusion Study, which followed 725 patients, iris or angle vessels appeared in 117 eyes over three years5. The risk sits mostly with eyes that lost a large area of retinal blood supply. Two things are in your hands: keep every scheduled visit, and call the same day if the eye becomes painful or red.
How a Blocked Retinal Vein Turns Into Glaucoma
When the main vein draining the retina is blocked, blood and fluid spill out into the retina6. Circulation slows, and parts of the retina stop getting enough oxygen. Retina short of oxygen releases signaling chemicals, including vascular endothelial growth factor, usually shortened to VEGF7. VEGF is a growth signal that builds new plumbing where circulation has failed. The trouble is that it spreads through the whole eye, including the front.
The vessels VEGF builds are thin-walled, leaky, and wrapped in a sheet of scar-like tissue. Early on they appear as tiny tufts at the pupil edge, then cross into the drainage meshwork, and if the process continues the membrane contracts and pulls the angle shut3. Fluid is made inside your eye all day and has to leave at the same rate. Block the exit and pressure rises, which damages the optic nerve. So treatment aims at the growth signal, not just the pressure.
The difference between the two patterns drives your monitoring plan. The Central Vein Occlusion Study drew the line at ten disc areas of capillary non-perfusion on dye photography, calling those eyes ischemic and the rest non-ischemic7. Non-ischemic does not mean safe forever. In that study, 81 of 547 eyes that looked well perfused at the start had converted to the ischemic pattern by four months, and 34 of every 100 had converted by three years5. Monitoring continues even when the first pictures look reassuring.
If your blockage was in a branch vein, this page describes a smaller risk for you. Eyes with a branch vein occlusion and significant capillary non-perfusion can grow new vessels on the retina and bleed into the vitreous, but are much less likely to develop neovascular glaucoma than eyes with a central or hemi-central occlusion7. Hemi-central occlusions affect half the retina and behave more like central ones. They carry an increased risk of late iris and angle vessel growth with raised pressure7. Ask which pattern you have.
Who Is Most Likely to Develop Neovascular Glaucoma
Your first examination collects most of what predicts this complication. A relative afferent pupillary defect, a pupil that reacts sluggishly when light is swung between the eyes, tracks the level of ischemia and marks eyes at risk of new vessel growth7. In a cohort of 98 eyes with a new central vein occlusion, that finding and worse starting vision were the strongest predictors, with 1 of 25 eyes seeing 20/50 or better developing neovascular glaucoma compared with 12 of 73 eyes that saw worse8. Poor starting vision is a signal, not a sentence.
Read these as group averages, not a forecast for your eye. Roughly 25 of every 100 people with a central vein occlusion develop new vessels on the iris7. In eyes with the ischemic pattern, reported figures within six months were about 49 of every 100 for iris vessels, about 39 of every 100 for angle vessels, and about 29 of every 100 for neovascular glaucoma4. In the 98-eye cohort, 13 developed neovascular glaucoma during follow-up8.
You cannot change how much retina the blockage starved. What sits alongside it is another matter. Blood pressure, diabetes, blood sugar and cholesterol control are part of standard care after a vein occlusion, coordinated with your primary care doctor7. High blood pressure was associated with a higher rate of neovascular glaucoma in the 98-eye cohort8. Attendance is the other lever: a kept visit is where new vessels get caught before your pressure rises.
Symptoms: What You May Notice and What You May Not
The disease runs in stages: new vessels on the iris with normal eye pressure, then an open-angle stage with raised pressure, then a stage where the angle is pulled closed4. New vessels on the iris and in the angle appear before the pressure goes up3. In that first stage you feel nothing and see no change. Only an examination finds it, which is when treatment is easiest.
Symptoms arrive with the pressure, not with the vessels. The most common complaints in neovascular glaucoma are eye pain and decreased vision3, alongside discomfort and redness of the eye2. A sharp rise in eye pressure can also bring severe pain in the eye or brow, rainbows or halos around lights, headache, nausea and vomiting, with blurred vision, halos and a mild ache as earlier warnings1. Nausea surprises people: an eye problem really can make you feel sick to your stomach.
A red, uncomfortable eye has more than one explanation, so it is worth being examined rather than guessing. Dry eye, a surface scratch, inflammation inside the eye and other pressure spikes all cause redness and ache. Corneal swelling, blood in the front chamber and visible new vessels on the iris and angle are what an examiner looks for to separate neovascular glaucoma from the alternatives3. Telling them apart takes a slit lamp and a pressure check.
How Your Eye Doctor Checks for It
The examination that matters most takes two minutes, before your eyes are dilated. Recommended follow-up includes undilated slit-lamp examination of the iris with gonioscopy, a mirrored contact lens that lets the doctor look into the drainage angle, monthly for six months after a central vein occlusion and in ischemic eyes after anti-VEGF injections are stopped7. Gonioscopy is done before dilating drops go in, which matters most in ischemic eyes, in raised pressure, and where the risk of iris vessels is high7.
Every visit includes a pressure reading, since the number can climb quietly. Pressure measurement, pupil assessment and a dilated look at the back of the eye are part of standard follow-up after a vein occlusion7. If it is up, your doctor will study the optic nerve and may order a visual field test. Raised pressure is what can damage the optic nerve in this condition4.
Imaging answers the question behind your risk: how much retina lost circulation. Fluorescein angiography, a dye study, is used to judge the extent of the blockage, the degree of ischemia and the extent of macular swelling7. Optical coherence tomography, a scan that maps retinal layers, is used at follow-up when appropriate7. Ask to see your own angiogram; knowing which end of that range your eye sits at makes the schedule feel less arbitrary.
This is the shape of the schedule most people follow after a central vein occlusion. Your own plan may be tighter or looser, and the reason should be explained to you.
| Timing | What the visit checks | Why it matters |
|---|---|---|
| Monthly, first 6 months | Undilated iris exam, gonioscopy, pressure, vision | The window when most new vessels appear |
| After stopping injections | The same checks, resumed monthly in ischemic eyes | The growth signal can return once treatment pauses |
| Any new pain or redness | Same-day pressure and angle check | Symptoms mean pressure may already be high |
Treatment: Turning Off the Signal and Lowering the Pressure
Anti-VEGF injections act on the growth signal itself, which is why they are often the first move. They are commonly used to treat macular swelling, reduce the severity of front-of-the-eye vessel growth and lower the risk of further growth, and are added on for iris or angle vessels, although there is no phase 3 trial evidence for that specific use7. The effect is temporary. In one cohort, anti-VEGF delayed the onset of neovascular glaucoma rather than removing the risk, with a median of about 150 days once the timing of the last injection was accounted for8. That is why injections are usually paired with laser.
Laser treats the starved retina that keeps making the growth signal. For iris or retinal new vessels after a central vein occlusion, dense peripheral panretinal photocoagulation is advised, it lowers the risk of iris vessel growth progressing, and anti-VEGF can be added if vessel growth continues after complete laser7. Panretinal photocoagulation is described as the mainstay of treatment for neovascular glaucoma3. Laser does not usually improve the vision you already have7. It protects the eye from what comes next.
Patients often ask why laser is not done up front on every ischemic eye. It was tested. In a randomized trial of 181 eyes with ischemic central vein occlusion, early preventive laser did not reliably stop iris or angle vessels from appearing, and when they did appear they regressed within a month of prompt laser in 18 of 32 eyes not treated before, versus 4 of 18 eyes already given preventive laser9. That trial group recommended frequent early follow-up with undilated iris examination and gonioscopy, then prompt laser at the first sign of vessels9. Monitoring here is an evidence-based choice, not a delay.
Pressure control runs in parallel with treating the vessels. Pressure-lowering medication is used, though drops alone are often not enough, and a glaucoma drainage device or laser cyclophotocoagulation, a treatment that reduces fluid production, may be needed2. Topical medication, trabeculectomy, valved and non-valved drainage implants, and cyclophotocoagulation for eyes with limited visual potential are all part of the surgical range3. Which one fits depends on your pressure, your angle and how much vision the eye still has, and that decision belongs to a glaucoma specialist who has examined you.
Treatment intensity tracks the stage.
| Stage | What is happening | Where treatment aims |
|---|---|---|
| New vessels, normal pressure | Vessels on the iris, angle still open | Anti-VEGF and panretinal laser |
| Raised pressure, open angle | Meshwork blocked by vessels | The above plus pressure-lowering medication |
| Angle pulled closed | Scar tissue has sealed the drain | Drainage surgery or cyclophotocoagulation |
Risks, Outlook, and Daily Life
Neovascular glaucoma is described as always challenging to treat, though in many cases some vision can be preserved, especially when it is detected and treated early2. Panretinal laser does not usually improve visual acuity even when it controls the vessels7. Vision after a central vein occlusion depends mostly on the occlusion itself. Treatment protects what remains, and the comfort of the eye. Ask your own doctor what is realistic rather than reading a group average as your outcome.
Some eyes reach this diagnosis with very little vision left, and the goal changes accordingly. Cyclophotocoagulation is used in eyes with limited visual potential3, where the aim is a comfortable eye at a normal pressure rather than a change on the eye chart. That is a legitimate goal, not giving up. A painful eye with no useful sight is a real quality-of-life problem, and it has its own treatments. Say plainly if pain rather than vision is what bothers you most, since it changes the options offered.
The conditions that led to one vein occlusion are still present, so the other eye deserves attention. Risk is higher over age 50 and in people with high blood pressure, diabetes, glaucoma and hardened arteries6. People who have had a vein occlusion also carry a higher rate of cardiovascular disease, which is why primary care awareness of that link is part of the care plan7. In practice: keep your blood pressure appointments, take your medication, and report sudden vision change in the good eye right away.
When to Call Your Eye Doctor
Call the office the same day, without waiting for your next visit, if any of these start in that eye.
- Eye pain or brow ache, mild or severe.
- Redness that does not clear within a few hours.
- Halos or rainbows around lights.
- A further drop in vision.
- Headache with nausea or vomiting.
These are symptoms of a sharp rise in eye pressure, and people who have them should be checked as soon as possible1. Eye pain and decreased vision are the most common complaints in neovascular glaucoma3, and early diagnosis and prompt treatment are described as essential4.
Some changes are not emergencies but should not wait for a routine appointment. Call within a week for gradually increasing blur, new floaters, a change in the look of the iris, or a new shadow in your side vision. Also call if your injections were stopped and you are unsure when your next examination is due. Monitoring is resumed monthly in ischemic eyes after anti-VEGF injections are discontinued, specifically to detect new vessel growth7. Monitoring is advised after every vein occlusion because non-ischemic eyes can become ischemic over time7. If you have missed appointments, call and restart.
Common Questions About Neovascular Glaucoma After a Vein Occlusion
No. The name marks the busiest part of the risk period, not a deadline. Neovascular glaucoma commonly presents around three months after the ischemic event, but reported cases range from two weeks to several years afterward, with most occurring within the first six months3. Treat the 90-day mark as the middle of a window, not a date to survive. Monitoring continues past it, and a normal examination at three months is reassuring without being final.
Skipping is the one choice with a clear downside, because the earliest stage has no symptoms at all: new vessels on the iris and angle appear before the pressure rises3. The visit exists to find that silent stage, when treatment works best. Monthly examination for six months is the recommended cadence after a central vein occlusion7. If a date does not work, move it rather than dropping it.
They help, but they are not a shield. Anti-VEGF agents reduce the severity of front-of-the-eye vessel growth and lower the risk of further vessel growth7. In one cohort, though, anti-VEGF delayed rather than removed the onset of neovascular glaucoma, with a median of about 150 days once the timing of the last injection was accounted for8. That is why monitoring is deliberately resumed after injections stop, and why laser is added when vessels actually appear.
Your risk is meaningfully lower, though not zero. Eyes with a branch vein occlusion and significant capillary non-perfusion can develop retinal vessel growth and vitreous bleeding, but are much less likely to develop neovascular glaucoma than eyes with a central or hemi-central occlusion7. Ask which pattern your scans show, since hemi-central occlusions behave more like central ones. Your follow-up still includes pressure checks, so ask how closely your iris and angle will be watched.
No, and the difference matters. Open-angle glaucoma, the most common type, comes on gradually as the eye drains fluid less well, is painless with no vision change at first, and is commonly managed with daily pressure-lowering drops10. Neovascular glaucoma is a secondary glaucoma driven by a condition that reduced blood flow to the retina, and pressure-lowering drops alone are often not enough2. Treatment has to address the oxygen-starved retina behind it, usually with injections and laser, alongside pressure control. The timeline is months rather than decades.
They can regress, and that is the goal of prompt treatment. In a randomized trial, iris or angle vessels regressed within one month of prompt panretinal laser in 18 of 32 eyes not previously treated9. Regression is more likely the earlier vessels are caught, which is the practical argument for the schedule. Once scar tissue has pulled the angle closed, treating the vessels no longer reopens it, and pressure control needs its own surgical route.
More Questions Patients Ask About This Window
It appears to. In a cohort of 98 eyes with a new central vein occlusion, high blood pressure was associated with a higher rate of neovascular glaucoma8. Blood pressure, blood sugar and cholesterol control are part of standard care after a vein occlusion7. Treat that appointment as an eye appointment too. It is one of the few levers genuinely in your hands.
Not entirely, which is why monitoring continues. In the Central Vein Occlusion Study, 81 of 547 well perfused eyes had converted to the ischemic pattern by four months, and 34 of every 100 had converted by three years5. A non-ischemic result at the first visit is good news about your current risk, not a permanent label. Repeat imaging keeps it current, and the plan is adjusted if it changes.
Dense peripheral panretinal photocoagulation is advised when iris or retinal new vessels appear after a central vein occlusion, with anti-VEGF added if vessel growth continues after complete laser7. Your pressure is measured, your angle examined by gonioscopy, and laser is often scheduled quickly. An injection may be given first to calm the vessels and improve the view. You will then be seen more often for a while.
Not by itself. This complication follows the blocked vein in that eye, so the other eye is at risk only if it has its own occlusion or another condition that starves the retina of oxygen. Risk of a vein occlusion is higher over age 50 and with high blood pressure, diabetes, glaucoma and hardened arteries6, and those factors are shared by both eyes. Managing them, and reporting sudden vision change in the good eye right away, is the sensible response.
Bring this list to your next appointment. The answers shape how often you need to be seen.
- Was my occlusion central, hemi-central, or branch?
- Does my angiogram show the ischemic or the non-ischemic pattern?
- Do I have a relative afferent pupillary defect?
- How often will you do gonioscopy and an undilated iris examination, and for how many months?
- When my injections stop, what is the monitoring plan?
- What number do I call after hours if my eye becomes painful or red?
- If my pressure rises, do I see retina, glaucoma, or both?
- American Academy of Ophthalmology, EyeSmart (2020). What Are Common Glaucoma Symptoms?.
- Glaucoma Research Foundation (2025). Neovascular Glaucoma.
- American Academy of Ophthalmology, EyeNet Magazine (2016). Diagnosis and Management of Neovascular Glaucoma.
- Frontiers in Medicine (PubMed Central PMC10800625) (2024). The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion.
- Archives of Ophthalmology, Central Vein Occlusion Study Group (1997). Natural history and clinical management of central retinal vein occlusion (CVOS Group M report).
- American Academy of Ophthalmology, EyeSmart (2025). What Is Central Retinal Vein Occlusion?.
- American Academy of Ophthalmology (2019). Retinal Vein Occlusions Preferred Practice Pattern.
- American Journal of Ophthalmology (PubMed Central PMC6642681) (2019). Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion.
- Ophthalmology, Central Vein Occlusion Study Group (1995). A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion (CVOS Group N report).
- American Academy of Ophthalmology, EyeSmart (2026). Understanding Glaucoma: Symptoms, Causes, Diagnosis, Treatment.